Correlation among HIF-1α,ERCC1 genetic polymorphisms and outcome of NSCLC patients receiving platinum-based chemotherapy
10.3969/j.issn.1006-5725.2016.03.012
- VernacularTitle:晚期非小细胞肺癌HIF－1α、ERCC1基因多态性与铂类药物疗效的关系
- Author:
Mingzhen ZHU
;
Haiyan XU
;
Hua JIANG
- Publication Type:Journal Article
- Keywords:
Non-small cell carcinoma;
Platinum;
Gene polymorphism
- From:
The Journal of Practical Medicine
2016;32(3):385-388
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the relationship among HIF-1α, ERCC1 gene polymorphisms and the effects of platinum-based chemotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) Methods HIF-1α C1772T and ERCC1 C118T loci were genotyped with PCR-RFLP method. The relationship between genotypes and the outcome of treatment as well as TTP was investigated. Results HIF-1α and ERCC1 of 102 patients were under the Hardy-Weinberg equilibrium. Patients with HIF-1α CT+TT genotype showed a significantly higher chemotherapeutic efficiency compared with patients with CC genotype; Patients with ERCC1 CC genotype showed a significantly higher chemotherapeutic efficiency compared with patients with CT+TT genotype. The median TTP was 7.0 months for the 98 patients followed-up; 7.0 months for HIF-1α CT+TT genotype, and 6.0 months for CC genotype, and the difference showed no significance; The median TTP was 7.0 months for ERCC1 CC genotype, and 6.0 months for CT+TT genotype, and the difference was statistically significant. Conclusions Patients with HIF-1α CT+TT genotype or ERCC1 CC genotype have showed higher chemotherapeutic efficiency, and patients with ERCC1 CC genotype show longer median TTP.
